Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Recommendation of “Hold” by Analysts

Pediatrix Medical Group, Inc. (NYSE:MD) has earned an average rating of “Hold” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $19.80.

Several brokerages have recently weighed in on MD. UBS Group decreased their target price on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a research note on Tuesday, February 24th. Zacks Research lowered shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Pediatrix Medical Group in a research report on Friday, February 20th. Truist Financial lowered their target price on Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a research note on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Monday, December 29th.

Insiders Place Their Bets

In other Pediatrix Medical Group news, CEO Mark S. Ordan sold 23,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $22.41, for a total transaction of $515,430.00. Following the completion of the sale, the chief executive officer owned 302,805 shares in the company, valued at $6,785,860.05. This trade represents a 7.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

Institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. lifted its holdings in Pediatrix Medical Group by 30.7% in the third quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock worth $69,114,000 after acquiring an additional 968,553 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Pediatrix Medical Group by 5.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,569,219 shares of the company’s stock valued at $76,349,000 after purchasing an additional 169,441 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Pediatrix Medical Group by 38.9% during the third quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock valued at $44,940,000 after purchasing an additional 751,109 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Pediatrix Medical Group by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 2,181,712 shares of the company’s stock worth $46,674,000 after purchasing an additional 14,421 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Pediatrix Medical Group by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,552,585 shares of the company’s stock worth $33,210,000 after purchasing an additional 105,345 shares during the period. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock opened at $19.79 on Monday. The firm has a market capitalization of $1.64 billion, a PE ratio of 10.20 and a beta of 0.79. Pediatrix Medical Group has a one year low of $11.84 and a one year high of $24.99. The stock’s 50 day moving average price is $21.11 and its 200 day moving average price is $19.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.66 and a current ratio of 1.66.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Thursday, February 19th. The company reported $0.50 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by ($0.03). The firm had revenue of $493.77 million during the quarter, compared to analyst estimates of $486.23 million. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The firm’s revenue was down 1.7% compared to the same quarter last year. During the same period last year, the business earned $0.51 EPS. As a group, sell-side analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.